Drug intelligence / Profile preview

Healiva 004

Development stage: Preclinical
Lead developer: Healiva
Modality: Cell Therapies
Administration: Topical

Overview

Healiva 004 is an autologous blood patch therapy currently in preclinical development by Healiva for the treatment of chronic wounds, including Venous Leg Ulcers (VLUs) and Diabetic Foot Ulcers (DFUs). The therapy is designed to be prepared at the point of care from a patient's own blood and applied topically to the wound site. It functions by delivering a concentrated matrix of blood-derived components, such as a fibrin clot matrix, platelets, and various growth factors. This biological scaffold and signaling environment are intended to stimulate the body's natural healing mechanisms, promote tissue regeneration, and achieve wound closure in early-stage chronic wounds.

Other names: Healiva blood patch

Beyond the preview

Go deeper on Healiva 004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Healiva 004.

Explore the full profile